cagrisema cagrilintide semaglutide phase 3 obesity CagriSema: a novel dual-pathway approach to target and its complications Original Article: Cagrilintide–Semaglutide in Adults

Rojas, M., et al

Peptides, PRP, and topical scalp treatments may help maintain stronger, healthier follicles

Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss

Semaglutide, the active ingredient of both oral and injectable Wegovy, copies GLP-1

Arch Biochem Biophys 574:108119 Zmock M, Janeek , Obinger C (2017) Fungal hybrid B heme peroxidases-unique fusions of a heme peroxidase domain with a carbohydrate-binding domain

A peptide that has lost its shape cannot effectively bind to the GLP-1 receptors in your body